Sigara Bırakma Tanı ve Tedavi Uzlaşı Raporu (2014)

Sigaranın Bırakılmasında Farmakolojik Tedavi
ancak 24 haftalık tedavinin sigarayı 6 ay ve 1
yıl için bırakmış kalma başarılarını arttırdığı da
görülmüştür . Tedavi süresinin uzatılmasında nüks
eğilimi olan olgular için düşünülebilir. Ancak sigara
bırakmada yaklaşımları sırasında farmakoterapiye
eşlik eden davranış desteği ve motivasyonel destek
yöntemlerinin sigara bırakma başarısını arttıracağı
unutulmamalıdır.
KAYNAKLAR
1. Henningfield, JE, Miyasato, K, Jasinski,
DR. Abuse liability and pharmacodynamic
characteristics of intravenous and inhaled
nicotine. J Pharmacol Exp Ther 1985; 234
2. (Richmond, RL, Kehow, L, de Almeida Neto,
AC. Three year continuous abstinence in a
smoking cessation study using the nicotine
transdermal patch. Heart 1997; 78:617
3. Hurt, RD, Sachs, DPL, Glover, ED, et al. A
Comparison of sustained-release buproprion
and placebo for smoking cessation. N Engl J
Med 1997; 337:1195
4. Jorenby, DE, Leischow, SJ, Nides, MA, et al. A
controlled trial of sustained-release bupropion,
a nicotine patch, or both for smoking cessation.
N Engl J Med 1999; 340:685
5. (Simon, JA, Duncan, C, Carmody, TP, Hudes, ES.
Bupropion for smoking cessation: a randomized
trial. Arch Intern Med 2004; 164:1797
6. Hughes JR, Stead LF, Lancaster T. Antidepressants
for smoking cessation. Cochrane Database Syst
Rev. 2007 Jan 24;(1):CD000031
7. Jime´nez-Ruiz C.A. Pharmacological treatment
for smoking cessation. Eur Respir Mon 2008;
42: 74-97
8. Gonzales D, Rennard SI, Nides M, Oncken
C, Azoulay S, Billing CB, Watsky EJ, Gong J,
Williams KE, Reeves KR; Varenicline Phase
3 Study Group. Varenicline, an alpha4beta2
nicotinic acetylcholine receptor partial agonist,
vs sustained-release bupropion and placebo for
smoking cessation: a randomized controlled
trial. JAMA. 2006 . 5;296(1):47-55
9. Jorenby DE, Hays JT, Rigotti NA, Azoulay S,
Watsky EJ, Williams KE, Billing CB, Gong J,
Reeves KR; Varenicline Phase 3 Study Group.
Efficacy of varenicline, an alpha4beta2
nicotinic acetylcholine receptor partial agonist,
vs placebo or sustained-release bupropion for
smoking cessation: a randomized controlled
trial. JAMA. 2006: 5;296(1):56-63.
10. Nides M, Oncken C, Gonzales D, Rennard S,
Watsky EJ, Anziano R, Reeves KR. Smoking
cessation with varenicline, a selective
alpha4beta2 nicotinic receptor partial agonist:
results from a 7-week, randomized, placeboand
bupropion-controlled trial with 1-year
follow-up. Arch Intern Med. 2006 Aug
14-28;166(15):1561-8.
11. Pachas GN, Cather C, Pratt SA, et al. Varenicline
for Smoking Cessation in Schizophrenia: Safety
and Effectiveness in a 12-Week, Open-Label
Trial. J Dual Diagn. 2012;8(2):117-125
12 Cerimele JM, Durango A. Does varenicline
worsen psychiatric symptoms in patients with
schizophrenia or schizoaffective disorder? A
review of published studies. J Clin Psychiatry.
2012;73(8):e1039-47.
13. European Smoking Cessation Guidelines:
The authoritative guide to a comprehensive
understanding of the implications and
implementation of treatments and strategies to
treat tobacco dependence. Revised 1st edition.
October 2012.
14. Judith J Prochaska, Joan F Hilton. Risk
of cardiovascular serious adverse events
associated with varenicline use for tobacco
cessation: systematic review and meta-analysis.
BMJ 2012;344:e2856 doi: 10.1136/bmj.e2856
(Published 4 May 2012)
15. Svanström H, Pasternak B, Hviid A. Use of
varenicline for smoking cessation and risk
of serious cardiovascular events: nationwide
cohort study. BMJ. 2012: 8;345:e7176
41